AstraZeneca PLC closed 20.36% short of its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca PLC has acquired a significant stake of 15.86% in Niox Group PLC, according to a recent company filing. This move ...

CSPC Pharmaceutical Group Ltd. announced June 13 that it struck a potential $5.33 billion deal with Astrazeneca plc to ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

Friday’s deal with CSPC fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...

AstraZeneca PLC closed 19.20% below its 52-week high of £133.88, which the company achieved on September 3rd.